Swedish patients risk being without the Alzheimer's medicine lecanemab, despite it being approved in the EU, reports Sveriges Radios Ekot.
The reason is the price negotiations currently underway between the pharmaceutical company and the Council for new therapies.
This is the first treatment that has an effect on the disease itself in Alzheimer's disease, but the effects are quite modest. It's about a six-month delay of the disease, says Linus Jönsson, professor of health economics at the Karolinska Institute, to Ekot.
This means that there is a limit to how much we can be willing to pay for this medicine.
